<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39193326</PMID><DateRevised><Year>2024</Year><Month>08</Month><Day>29</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1663-9812</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in pharmacology</Title><ISOAbbreviation>Front Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Efficient analysis of adverse drug events and toxicological mechanisms of newly marketed drugs by integrating pharmacovigilance and network toxicology: selumetinib as an example.</ArticleTitle><Pagination><StartPage>1432759</StartPage><MedlinePgn>1432759</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1432759</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fphar.2024.1432759</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To integrate pharmacovigilance and network toxicology methods to explore the potential adverse drug events (ADEs) and toxic mechanisms of selumetinib, and to provide a reference for quickly understanding the safety and toxicological mechanisms of newly marketed drugs.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Taking selumetinib as an example, this study integrated pharmacovigilance methods based on real-world data and network toxicology methods to analyze its ADE and its potential toxicological mechanism. First, the ADE reports of selumetinib were extracted from the US Food and Drug Administration (FDA) adverse event reporting system (FAERS), and the ADE signals were detected by reporting odds ratio (ROR) and UK medicines and healthcare products regulatory agency (MHRA) methods. The ADE signals were classified and described according to the preferred terms (PTs) and system organ class (SOC) derived from the Medical Dictionary for Regulatory Activities (MedDRA). The network toxicology method was used to analyze the toxicological mechanism of the interested SOCs. The specific steps included predicting the potential targets of selumetinib using TOXRIC, STITCH, ChEMBL, CTD, SwissTargetPreditcion, and Super-PRED databases, collecting the targets of SOC using GeneCards database, conducting protein-protein interaction (PPI) analysis through STRING database, conducting gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) analysis through DAVID database, and testing the molecular affinity using AutoDock software.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 1388 ADE reports related to selumetinib were extracted, and 53 positive signals were detected by ROR and MHRA methods, of which 20 signals were not mentioned in the package insert, including ingrowing nail, hyperphosphatemia, cardiac valve disease, hematuria, neutropenia, etc. Analysis of the toxicological mechanism of six SOCs involved in positive ADE signals revealed that the key targets included EGFR, STAT3, AKT1, IL6, BCL2, etc., and the key pathways included PI3K/Akt pathway, apoptosis, ErbB signaling pathway, and EGFR tyrosine kinase inhibitor resistance, etc. Molecular docking assays showed spontaneous binding of selumetinib to key targets in these pathways.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">The pharmacovigilance analysis identified some new potential ADEs of selumetinib, and the network toxicology analysis showed that the toxic effects of selumetinib may be related to PI3K/Akt pathway, apoptosis, ErbB signaling pathway, EGFR tyrosine kinase inhibitor resistance and other pathways.</AbstractText><CopyrightInformation>Copyright © 2024 Xiong, Lei, Wang, Zhang, Liu, Wang, Liu and Lai.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Xiong</LastName><ForeName>Rui</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Jiangbei Campus of The First Affiliated Hospital of Army Medical University (The 958th Hospital of Chinese People's Liberation Army), Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Lei</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Daping Hospital, Army Medical University, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Wang</LastName><ForeName>Lu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Jiangbei Campus of The First Affiliated Hospital of Army Medical University (The 958th Hospital of Chinese People's Liberation Army), Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Shipeng</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Jiangbei Campus of The First Affiliated Hospital of Army Medical University (The 958th Hospital of Chinese People's Liberation Army), Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Hengxu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Jiangbei Campus of The First Affiliated Hospital of Army Medical University (The 958th Hospital of Chinese People's Liberation Army), Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Hongping</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, The First Affiliated Hospital of Army Medical University, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Tao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Navy No.971 Hospital, Qingdao, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Xiaodan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Jiangbei Campus of The First Affiliated Hospital of Army Medical University (The 958th Hospital of Chinese People's Liberation Army), Chongqing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Pharmacol</MedlineTA><NlmUniqueID>101548923</NlmUniqueID><ISSNLinking>1663-9812</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">food and drug administration adverse event reporting system</Keyword><Keyword MajorTopicYN="N">network toxicology</Keyword><Keyword MajorTopicYN="N">neurofibromatosis</Keyword><Keyword MajorTopicYN="N">pharmacovigilance</Keyword><Keyword MajorTopicYN="N">selumetinib</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>28</Day><Hour>8</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>28</Day><Hour>4</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39193326</ArticleId><ArticleId IdType="pmc">PMC11347787</ArticleId><ArticleId IdType="doi">10.3389/fphar.2024.1432759</ArticleId><ArticleId IdType="pii">1432759</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Anderson M. K., Johnson M., Thornburg L., Halford Z. (2021). A review of selumetinib in the treatment of neurofibromatosis type 1–related plexiform neurofibromas. Ann. Pharmacother. 56, 716–726. 10.1177/10600280211046298</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/10600280211046298</ArticleId><ArticleId IdType="pubmed">34541874</ArticleId></ArticleIdList></Reference><Reference><Citation>Aziz M., Ejaz S. A., Alsfouk B. A., Sultan A., Li C. (2023b). Identification of potential inhibitors against E.coli via novel approaches based on deep learning and quantum mechanics-based atomistic investigations. Arch. Biochem. Biophys. 747, 109761. 10.1016/j.abb.2023.109761</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.abb.2023.109761</ArticleId><ArticleId IdType="pubmed">37734644</ArticleId></ArticleIdList></Reference><Reference><Citation>Aziz M., Sarfraz M., Khurrum Ibrahim M., Ejaz S. A., Zehra T., Ogaly H. A., et al. (2023a). Evaluation of anticancer potential of tetracene-5,12-dione (A01) and pyrimidine-2,4-dione (A02) via caspase 3 and lactate dehydrogenase cytotoxicity investigations. PLoS One 18 (12), e0292455. 10.1371/journal.pone.0292455</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0292455</ArticleId><ArticleId IdType="pmc">PMC10734984</ArticleId><ArticleId IdType="pubmed">38127898</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbar T., Jaffer Sathick I., Syndrome T. L. (2021). Adv. Chronic Kidney Dis. 28, 438–446.e431. 10.1053/j.ackd.2021.09.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ackd.2021.09.007</ArticleId><ArticleId IdType="pubmed">35190110</ArticleId></ArticleIdList></Reference><Reference><Citation>Beech J., Germetaki T., Judge M., Paton N., Collins J., Garbutt A., et al. (2018). Management and grading of EGFR inhibitor-induced cutaneous toxicity. Future Oncol. 14, 2531–2541. 10.2217/fon-2018-0187</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fon-2018-0187</ArticleId><ArticleId IdType="pubmed">29727211</ArticleId></ArticleIdList></Reference><Reference><Citation>Belli C., Repetto M., Anand S., Porta C., Subbiah V., Curigliano G. (2023). The emerging role of PI3K inhibitors for solid tumour treatment and beyond. Br. J. Cancer 128, 2150–2162. 10.1038/s41416-023-02221-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41416-023-02221-1</ArticleId><ArticleId IdType="pmc">PMC10241926</ArticleId><ArticleId IdType="pubmed">36914722</ArticleId></ArticleIdList></Reference><Reference><Citation>Böhm R., Höcker J., Cascorbi I., Herdegen T. (2012). OpenVigil—free eyeballs on AERS pharmacovigilance data. Nat. Biotechnol. 30, 137–138. 10.1038/nbt.2113</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.2113</ArticleId><ArticleId IdType="pubmed">22318027</ArticleId></ArticleIdList></Reference><Reference><Citation>Borgia P., Piccolo G., Santangelo A., Chelleri C., Viglizzo G., Occella C., et al. (2024). Dermatologic effects of selumetinib in pediatric patients with neurofibromatosis type 1: clinical challenges and therapeutic management. J. Clin. Med. 13, 1792. 10.3390/jcm13061792</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm13061792</ArticleId><ArticleId IdType="pmc">PMC10971430</ArticleId><ArticleId IdType="pubmed">38542016</ArticleId></ArticleIdList></Reference><Reference><Citation>Caiffa T., Tessitore A., Magnolato A., Petz M., Bobbo M., Chicco D., et al. (2022). Characterization of cardiac function by echocardiographic global longitudinal strain in a cohort of children with neurofibromatosis type 1 treated with selumetinib. Pediatr. Drugs 25, 217–224. 10.1007/s40272-022-00551-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40272-022-00551-w</ArticleId><ArticleId IdType="pubmed">36529809</ArticleId></ArticleIdList></Reference><Reference><Citation>Casey D., Demko S., Sinha A., Mishra-Kalyani P. S., Shen Y.-l., Khasar S., et al. (2021). FDA approval summary: selumetinib for plexiform neurofibroma. Clin. Cancer Res. 27, 4142–4146. 10.1158/1078-0432.CCR-20-5032</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-20-5032</ArticleId><ArticleId IdType="pubmed">33712511</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow P. I., Shaffer K. M., Lohman M. C., LeBaron V. T., Fortuna K. L., Ritterband L. M. (2020). Examining the relationship between changes in personality and depression in older adult cancer survivors. Aging Ment. Health 24 (8), 1237–1245. 10.1080/13607863.2019.1594158</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13607863.2019.1594158</ArticleId><ArticleId IdType="pubmed">30939904</ArticleId></ArticleIdList></Reference><Reference><Citation>Daina A., Michielin O., Zoete V. (2019). SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res. 47, W357–W364. 10.1093/nar/gkz382</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkz382</ArticleId><ArticleId IdType="pmc">PMC6602486</ArticleId><ArticleId IdType="pubmed">31106366</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis A. P., Wiegers T. C., Johnson R. J., Sciaky D., Wiegers J., Mattingly Carolyn J. (2023). Comparative Toxicogenomics database (CTD): update 2023. Nucleic Acids Res. 51, D1257–D1262. 10.1093/nar/gkac833</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkac833</ArticleId><ArticleId IdType="pmc">PMC9825590</ArticleId><ArticleId IdType="pubmed">36169237</ArticleId></ArticleIdList></Reference><Reference><Citation>Dombi E., Baldwin A., Marcus L. J., Fisher M. J., Weiss B., Kim A., et al. (2016). Activity of selumetinib in neurofibromatosis type 1–related plexiform neurofibromas. N. Engl. J. Med. 375, 2550–2560. 10.1056/NEJMoa1605943</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1605943</ArticleId><ArticleId IdType="pmc">PMC5508592</ArticleId><ArticleId IdType="pubmed">28029918</ArticleId></ArticleIdList></Reference><Reference><Citation>Fangusaro J., Onar-Thomas A., Poussaint T. Y., Wu S., Ligon A. H., Lindeman N., et al. (2021). A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study. Neuro-Oncology 23, 1777–1788. 10.1093/neuonc/noab047</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/neuonc/noab047</ArticleId><ArticleId IdType="pmc">PMC8485450</ArticleId><ArticleId IdType="pubmed">33631016</ArticleId></ArticleIdList></Reference><Reference><Citation>Fangusaro J., Onar-Thomas A., Young Poussaint T., Wu S., Ligon A. H., Lindeman N., et al. (2019). Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncol. 20, 1011–1022. 10.1016/S1470-2045(19)30277-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(19)30277-3</ArticleId><ArticleId IdType="pmc">PMC6628202</ArticleId><ArticleId IdType="pubmed">31151904</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallo K., Goede A., Preissner R., Gohlke B.-O. (2022). SuperPred 3.0: drug classification and target prediction—a machine learning approach. Nucleic Acids Res. 50, W726–W731. 10.1093/nar/gkac297</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkac297</ArticleId><ArticleId IdType="pmc">PMC9252837</ArticleId><ArticleId IdType="pubmed">35524552</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross A. M., Dombi E., Wolters P. L., Baldwin A., Dufek A., Herrera K., et al. (2023). Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas. Neuro-Oncology 25, 1883–1894. 10.1093/neuonc/noad086</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/neuonc/noad086</ArticleId><ArticleId IdType="pmc">PMC10547508</ArticleId><ArticleId IdType="pubmed">37115514</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross A. M., Glassberg B., Wolters P. L., Dombi E., Baldwin A., Fisher M. J., et al. (2022). Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity. Neuro-Oncology 24, 1978–1988. 10.1093/neuonc/noac109</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/neuonc/noac109</ArticleId><ArticleId IdType="pmc">PMC9629448</ArticleId><ArticleId IdType="pubmed">35467749</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross A. M., Wolters P. L., Dombi E., Baldwin A., Whitcomb P., Fisher M. J., et al. (2020). Selumetinib in children with inoperable plexiform neurofibromas. N. Engl. J. Med. 382 (15), 1430–1442. 10.1056/NEJMoa1912735</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1912735</ArticleId><ArticleId IdType="pmc">PMC7305659</ArticleId><ArticleId IdType="pubmed">32187457</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutmann D. H., Ferner R. E., Listernick R. H., Korf B. R., Wolters P. L., Johnson K. J. (2017). Neurofibromatosis type 1. Nat. Rev. Dis. Prim. 3, 17004. 10.1038/nrdp.2017.4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.4</ArticleId><ArticleId IdType="pubmed">28230061</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Y., Li B., Yu X., Liu J., Zhao W., Zhang D., et al. (2024). Efficacy and safety of selumetinib in patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas: a systematic review and meta-analysis. J. Neurology 271, 2379–2389. 10.1007/s00415-024-12301-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-024-12301-8</ArticleId><ArticleId IdType="pubmed">38502338</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassan G., Seno M. (2022). ERBB signaling pathway in cancer stem cells. Adv. Exp. Med. Biol. 1393, 65–81. 10.1007/978-3-031-12974-2_3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-031-12974-2_3</ArticleId><ArticleId IdType="pubmed">36587302</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho A. L., Dedecjus M., Wirth L. J., Tuttle R. M., Inabnet W. B., Tennvall J., et al. (2022). Selumetinib plus adjuvant radioactive iodine in patients with high-risk differentiated thyroid cancer: a phase III, randomized, placebo-controlled trial (ASTRA). J. Clin. Oncol. 40, 1870–1878. 10.1200/JCO.21.00714</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.21.00714</ArticleId><ArticleId IdType="pmc">PMC9851689</ArticleId><ArticleId IdType="pubmed">35192411</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang S. (2023). Efficient analysis of toxicity and mechanisms of environmental pollutants with network toxicology and molecular docking strategy: acetyl tributyl citrate as an example. Sci. Total Environ. 905, 167904. 10.1016/j.scitotenv.2023.167904</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.scitotenv.2023.167904</ArticleId><ArticleId IdType="pubmed">37858827</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang J., Yoon H. M., Lee B. H., Kim P. H., Kim K. W. (2022). Efficacy and safety of selumetinib in pediatric patients with neurofibromatosis type 1. Neurology 98, 938–946. 10.1212/wnl.0000000000013296</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.0000000000013296</ArticleId><ArticleId IdType="pubmed">35017312</ArticleId></ArticleIdList></Reference><Reference><Citation>Legius E., Messiaen L., Wolkenstein P., Pancza P., Avery R. A., Berman Y., et al. (2021). Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet. Med. 23, 1506–1513. 10.1038/s41436-021-01170-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41436-021-01170-5</ArticleId><ArticleId IdType="pmc">PMC8354850</ArticleId><ArticleId IdType="pubmed">34012067</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni J., Tang X., Chen L. (2023). Medication overdose data analysis: a review of medication error reports in the FDA adverse event reporting system (FAERS). BMC Pharmacol. Toxicol. 24, 41. 10.1186/s40360-023-00681-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40360-023-00681-y</ArticleId><ArticleId IdType="pmc">PMC10403938</ArticleId><ArticleId IdType="pubmed">37542326</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunnery S. E., Mayer I. A. (2019). Management of toxicity to isoform α-specific PI3K inhibitors. Ann. Oncol. 30, x21–x26. 10.1093/annonc/mdz440</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdz440</ArticleId><ArticleId IdType="pmc">PMC6923786</ArticleId><ArticleId IdType="pubmed">31626273</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakaeda T., Tamon A., Kadoyama K., Okuno Y. (2013). Data mining of the public version of the FDA adverse event reporting system. Int. J. Med. Sci. 10, 796–803. 10.7150/ijms.6048</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijms.6048</ArticleId><ArticleId IdType="pmc">PMC3689877</ArticleId><ArticleId IdType="pubmed">23794943</ArticleId></ArticleIdList></Reference><Reference><Citation>Saleh M., Dib A., Beaini S., Saad C., Faraj S., El Joueid Y., et al. (2023). Neurofibromatosis type 1 system-based manifestations and treatments: a review. Neurol. Sci. 44, 1931–1947. 10.1007/s10072-023-06680-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-023-06680-5</ArticleId><ArticleId IdType="pubmed">36826455</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherman B. T., Hao M., Qiu J., Jiao X., Baseler M. W., Lane H. C., et al. (2022). DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. 50, W216–W221. 10.1093/nar/gkac194</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkac194</ArticleId><ArticleId IdType="pmc">PMC9252805</ArticleId><ArticleId IdType="pubmed">35325185</ArticleId></ArticleIdList></Reference><Reference><Citation>Stelzer G., Rosen N., Plaschkes I., Zimmerman S., Twik M., Fishilevich S., et al. (2016). The GeneCards suite: from gene data mining to disease genome sequence analyses. Curr. Protoc. Bioinforma. 54, 1.30.1–1.30.33. 10.1002/cpbi.5</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpbi.5</ArticleId><ArticleId IdType="pubmed">27322403</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk D., Kirsch R., Koutrouli M., Nastou K., Mehryary F., Hachilif R., et al. (2023). The STRING database in 2023: protein–protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 51, D638–D646. 10.1093/nar/gkac1000</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkac1000</ArticleId><ArticleId IdType="pmc">PMC9825434</ArticleId><ArticleId IdType="pubmed">36370105</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk D., Santos A., von Mering C., Jensen L. J., Bork P., Kuhn M. (2016). STITCH 5: augmenting protein–chemical interaction networks with tissue and affinity data. Nucleic Acids Res. 44, D380–D384. 10.1093/nar/gkv1277</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkv1277</ArticleId><ArticleId IdType="pmc">PMC4702904</ArticleId><ArticleId IdType="pubmed">26590256</ArticleId></ArticleIdList></Reference><Reference><Citation>Vervloet M. G., van Ballegooijen A. J. (2018). Prevention and treatment of hyperphosphatemia in chronic kidney disease. Kidney Int. 93, 1060–1072. 10.1016/j.kint.2017.11.036</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2017.11.036</ArticleId><ArticleId IdType="pubmed">29580635</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z. (2017). ErbB receptors and cancer. Methods Mol. Biol. 1652, 3–35. 10.1007/978-1-4939-7219-7_1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-7219-7_1</ArticleId><ArticleId IdType="pubmed">28791631</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu L., Yan B., Han J., Li R., Xiao J., He S., et al. (2023). TOXRIC: a comprehensive database of toxicological data and benchmarks. Nucleic Acids Res. 51, D1432–D1445. 10.1093/nar/gkac1074</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkac1074</ArticleId><ArticleId IdType="pmc">PMC9825425</ArticleId><ArticleId IdType="pubmed">36400569</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong R., Lei J., Pan S., Zhang H., Tong Y., Wu W., et al. (2023). Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system. Front. Pharmacol. 14, 1226086. 10.3389/fphar.2023.1226086</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2023.1226086</ArticleId><ArticleId IdType="pmc">PMC10538962</ArticleId><ArticleId IdType="pubmed">37781705</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong R., Wang X.-L., Wu J.-M., Tang Y., Qiu W.-Q., Shen X., et al. (2020). Polyphenols isolated from lychee seed inhibit Alzheimer's disease-associated Tau through improving insulin resistance via the IRS-1/PI3K/Akt/GSK-3β pathway. J. Ethnopharmacol. 251, 112548. 10.1016/j.jep.2020.112548</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jep.2020.112548</ArticleId><ArticleId IdType="pubmed">31917277</ArticleId></ArticleIdList></Reference><Reference><Citation>Zdrazil B., Felix E., Hunter F., Manners E. J., Blackshaw J., Corbett S., et al. (2024). The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res. 52, D1180–D1192. 10.1093/nar/gkad1004</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkad1004</ArticleId><ArticleId IdType="pmc">PMC10767899</ArticleId><ArticleId IdType="pubmed">37933841</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y., Cheng B., Chen Z., Li J., Liang H., Chen Y., et al. (2021). Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: a systematic review and network meta-analysis. Crit. Rev. Oncology/Hematology 160, 103305. 10.1016/j.critrevonc.2021.103305</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.critrevonc.2021.103305</ArticleId><ArticleId IdType="pubmed">33757838</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z., Du J.-F., Wang Q.-L., Qiu F.-N., Chen X.-Y., Liu F.-J., et al. (2023). An integrated strategy combining network toxicology and feature-based molecular networking for exploring hepatotoxic constituents and mechanism of Epimedii Folium-induced hepatotoxicity in vitro . Food Chem. Toxicol. 176, 113785. 10.1016/j.fct.2023.113785</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fct.2023.113785</ArticleId><ArticleId IdType="pubmed">37080529</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>